Media Coverage

Articles

March 6, 2018 Developing a pegfilgrastim biosimilar to increase patient access to cancer care

Nature Biopharma Dealmakers

January 11, 2018 How These Hospital Stakeholders Can Benefit Biosimilar Commercialization

Biosimilar Development

November 23, 2017 Perspectives on the future of pegfilgrastim biosimilars

GaBi Journal

October 9, 2017 Cinfa Banks On ‘Multi-Layered’ Scientific Advice As It Files For EU Pegfilgrastim Biosimilar Review

Pink Sheet

January 28, 2016 Cinfa Biotech: How Pharmacists Can Benefit Biosimilar Development

Biosimilar Development

Interviews

BIO-Europe® 2017
Interview with Dr. Rüdiger Jankowsky (Managing Director of Cinfa Biotech GmbH)
Cinfa BioTech CEO speaking at an event

Cinfa Biotech discusses biosimilar products approaching the market

During the recent BIO-Europe partnering conference in Berlin, Mike Ward, global director of content for Informa Pharma Insights, caught up with Ruediger Jankowsky, managing director of Cinfa Biotech GmbH, to discuss the company’s pipeline of biosimilar products for oncology and inflammatory diseases. Cinfa Biotech GmbH has one product under regulatory review in Europe, a biosimilar version of Amgen Inc.’s Neulasta (pegfilgrastim), which is used to treat chemotherapy-induced neutropenia.

The Spanish firm is now seeking partners to commercialize this biosimilar drug once approved by regulators in Europe and other regions. Cinfa Biotech’s Managing Director says the company will also submit the drug to the US FDA soon.

BIO-Europe® 2016
Interview with Dr. Rüdiger Jankowsky (Managing Director of Cinfa Biotech Gmbh)
Cinfa BioTech CEO speaking at an event

Cinfa Biotech outlines biosimilar development areas and deals opportunities

Cinfa Biotech’s managing director, Ruediger Jankowsky, chats with Mike Ward, global director of content for Informa Pharma Intelligence, about the company’s founding and focus on biosimilar drug development. They discuss Cinfa’s biosimilars business model, disease areas of focus and potential deals for the company in the near future.